Follow the 현대바이오 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 현대바이오 has published 49 insider filings. Market capitalisation: €593.5bn. The latest transaction was filed on 12 June 2026 (Other). Among the most active insiders: 씨앤팜. All data is free.
49
Insider Decl.
n/a
Thresholds
n/a
5 ops.
Buy Volume
n/a
9 ops.
Sell Volume
20Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,558 of 29,056 companies
16.1
score / 100
Value
22
Quality
10
FCF yld-6.0%
Earn yld-3.6%
EV/EBITDA·
ROE-24%
Gross mgn6.9%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Hyundai Bio es una empresa especializada en el sector de la salud y farmacéutico, cotiza en el mercado XKRX. Se enfoca en el desarrollo de soluciones biofarmacéuticas innovadoras.